This is a type of cancer where the cells look like a signet ring. It's a type of cancer that often starts in the stomach or intestines.
Every report comes from a Lived member, sent anonymously.
Have you had Gastrectomy for Signet Ring Cell Carcinoma?
Signet ring cell carcinoma (SRCC) is a type of adenocarcinoma, a cancer that starts in the glandular cells lining an organ. Its name describes how the cancer cells look under a microscope: each cell is filled with a droplet of mucus that pushes the nucleus to one edge, so the cell resembles a signet ring. About 90% of SRCC starts in the stomach. Much less often it begins in the colon or rectum, esophagus, pancreas, gallbladder, appendix, bladder, prostate or breast. SRCC matters because it tends to behave differently from other cancers in the same organ. Instead of forming a distinct lump, the cells often spread through the wall of the stomach or bowel, sometimes beneath lining that looks normal. They also have a tendency to spread to the lymph nodes and the lining of the abdomen (the peritoneum). Because early SRCC usually causes no symptoms, it is often found after it has already spread, which makes treatment more difficult.
Researchers do not yet know why the glandular cells in SRCC become cancerous. For most people there is no single identifiable cause. Changes in a gene called CDH1, which makes a protein that helps cells stick together, appear to play a role in many cases of stomach SRCC. The loss of that cell-to-cell grip helps explain why these cancers spread diffusely rather than as a solid mass. Colorectal SRCC has no single known cause either, although it tends to be diagnosed in younger people than more common bowel cancers. A small share of stomach SRCC is inherited. Hereditary diffuse gastric cancer is a family syndrome caused mostly by inherited CDH1 variants. It raises the risk of this kind of stomach cancer, often at a younger age than usual, and raises the risk of lobular breast cancer in women. How much the risk rises varies widely between families. Clues that a family may carry such a variant include stomach cancer diagnosed at a young age or in several relatives, or both diffuse stomach cancer and lobular breast cancer in the same family.
Because the early symptoms of stomach SRCC (indigestion, stomach discomfort or vague pain) are common and usually have harmless causes, diagnosis often starts with a clinician looking for a reason why such symptoms persist. For the stomach, an upper endoscopy is the key test: a thin, flexible camera is passed through the mouth to view the lining and take small tissue samples (a biopsy). For the colon, the equivalent test is a colonoscopy. A pathologist confirms SRCC by examining the biopsy under a microscope and finding the characteristic signet ring cells, sometimes with special stains. Because SRCC can spread under lining that looks normal, it can be missed on a first endoscopy, and repeat or multiple biopsies are sometimes needed. Once the diagnosis is made, staging tests show how far the cancer has spread. A CT (computed tomography) scan is the usual starting point, and a PET (positron emission tomography) scan may be added to look for spread elsewhere in the body. Blood tests check general health. Laboratory tests on the tumor look for markers (proteins or genetic features of the cancer cells that certain medicines target) such as HER2, PD-L1, claudin 18.2 and microsatellite instability (a pattern of DNA repair defects). For advanced cancer, these results help decide which targeted or immune medicines can be added to chemotherapy.
Treatment depends mostly on where the cancer started and its stage. It is planned by a team that usually includes a surgeon, a medical oncologist and sometimes a radiation oncologist, and most people receive more than one type of treatment. For stomach SRCC that has not spread to distant organs, surgery offers the best chance of cure. This usually means removing part or all of the stomach (a gastrectomy) along with nearby lymph nodes. Surgeons aim for wider margins of healthy tissue than with other stomach cancers because SRCC can extend unseen beneath the lining. Removing a tumor through an endoscope, without open surgery, is considered only for a small number of very early cancers that are small, confined to the innermost lining and not ulcerated. Chemotherapy is commonly given before and after surgery for more advanced but still removable stomach cancer, and for colorectal SRCC that has reached the lymph nodes, chemotherapy after surgery appears to improve survival. A practical limitation is that stomach SRCC often responds less well to chemotherapy than other stomach cancers, and specialists still debate whether chemotherapy before surgery helps or whether going straight to surgery is better. Radiation combined with chemotherapy is used in some situations, particularly for cancers at the junction of the esophagus and stomach. When the cancer has spread, chemotherapy aims to slow it, ease symptoms and extend life rather than cure it. For a few carefully selected people with limited spread to the abdominal lining, surgery to remove visible tumor followed by heated chemotherapy delivered directly into the abdomen (hyperthermic intraperitoneal chemotherapy, or HIPEC) may be considered at specialist centers, although its benefit in SRCC is uncertain. For advanced stomach or junction cancer, tests on the tumor (for HER2, PD-L1, claudin 18.2 and microsatellite instability) help decide whether a targeted medicine or an immunotherapy can be added to chemotherapy. Examples include trastuzumab (Herceptin) for HER2-positive tumors, pembrolizumab (Keytruda) or nivolumab (Opdivo) for tumors that show PD-L1, and zolbetuximab (Vyloy) for HER2-negative tumors that carry claudin 18.2, a marker often found in this diffuse type of stomach cancer. Because standard options have clear limits, clinical trials are a reasonable thing to ask about at any stage. People who carry an inherited CDH1 variant face a different decision: annual surveillance endoscopy with multiple biopsies, or a preventive total gastrectomy, which guidelines generally recommend for adult carriers. Annual surveillance endoscopy is an accepted alternative for carriers who decline or delay surgery. The choice weighs removing the organ at risk against permanent changes to eating and nutrition.
Outlook depends heavily on stage. When stomach SRCC is found early, while it is still confined to the inner layers of the stomach wall, several studies show that people do as well as or better than those with other early stomach cancers. Advanced SRCC is harder to treat. It often comes back after surgery, most commonly in the lining of the abdomen, and responds less predictably to chemotherapy. Colorectal SRCC also tends to have a poorer outlook than more common bowel cancers. Individual outcomes vary, and the care team can describe what is realistic for a particular stage. Surgery on the stomach is a major operation, with a hospital stay of about a week or more and several weeks of recovery at home. Afterward, digestion changes: some people have nausea, ongoing diarrhea or dumping syndrome, in which food moves too quickly into the intestine, and eating habits usually need adjusting with help from the care team. Chemotherapy brings its own fatigue and side effects over months. After treatment, regular follow-up visits and scans watch for recurrence. For advanced cancer, the goals shift toward controlling the disease and living as comfortably as possible. Palliative care, which focuses on relieving symptoms and treatment side effects, can be added at any stage alongside cancer treatment, not only at the end of life. Relatives of someone with stomach SRCC diagnosed young, or with a family history of stomach or lobular breast cancer, may be offered genetic counseling and testing.
See a clinician about indigestion, belly pain or other digestive symptoms that keep coming back or do not improve, especially if you have a family history of stomach cancer at a young age. A family pattern of stomach cancer, or of stomach cancer and lobular breast cancer together, is a reason to ask for genetic counseling even without symptoms. Arrange an evaluation soon for unexplained weight loss, trouble swallowing, vomiting that keeps returning, a small amount of blood in the stool, or yellowing of the skin or eyes. If you are already being treated for SRCC, report new or worsening symptoms to your care team rather than waiting for the next visit. Chemotherapy lowers the white blood cells that fight infection, so during treatment a fever of 100.4 F (38 C) or higher, or above the limit your team has given you, can be the first sign of a serious infection. Call the cancer team's urgent number right away, day or night, and follow their direction. Get emergency care for vomiting blood or material that looks like coffee grounds, black or bloody stools with dizziness or fainting, severe shortness of breath, or repeated vomiting with a swollen, painful belly and no stool or gas passing, which can mean the bowel is blocked.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Signet Ring Cell Carcinoma is like, what's helped you, or ask the community a question.